文献速递血液净化与透析水电解质与酸碱

西那卡塞使用者低钙血症与心血管死亡关联

Hypocalcemia and cardiovascular mortality in cinacalcet users.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

基于日本全国透析患者登记的前瞻性队列研究,纳入维持性血液透析或血液透析滤过患者,其中基线12.7%使用西那卡塞。采用三种Cox模型分析,发现时间依赖模型中最低钙十分位(校正钙<8.4 mg/dL)与心血管死亡风险升高显著相关,西那卡塞使用者及全部患者均如此,低钙血症尤其与猝死、出血性卒中、心衰和缺血性心脏病死亡相关。

要点

  • 时间依赖模型中校正钙<8.4 mg/dL与心血管死亡风险升高显著相关。
  • 西那卡塞使用者中该关联HR为1.32,全部患者中HR为1.15。
  • 低钙血症尤其与猝死、出血性卒中、心衰和缺血性心脏病死亡相关。

核心结论

  • 研究提示一过性低钙血症与心血管死亡风险升高相关,且不依赖于西那卡塞使用。
  • 应关注西那卡塞一过性诱导的低钙血症。

研究设计与样本

  • 9年前瞻性队列研究,基线数据于2009年底收集,使用日本全国透析患者登记数据。
  • 采用基线、时间依赖和时间平均三种Cox比例风险回归模型分析。

主要发现

  • 全队列中位观察期98个月(四分位距40-108),西那卡塞使用者中位观察期108个月(四分位距59-108)。
  • 2019年底存活者中四分之三持续拟钙剂治疗10年,对应年均脱落率2.9%。
  • 基线模型和时间平均模型中低钙血症与心血管死亡无显著关联。
  • 时间依赖模型中,最低钙十分位(校正钙<8.4 mg/dL)与心血管死亡显著相关:西那卡塞使用者HR 1.32(95%CI 1.00, 1.75),全部患者HR 1.15(95%CI 1.05, 1.26),参照组为校正钙8.7-8.9 mg/dL。
  • 低钙血症尤其与猝死、出血性卒中、心衰和缺血性心脏病死亡相关;无论是否使用西那卡塞,低钙血症患者致命和非致命心血管事件发生率均更高。

关键数值与推荐

  • 最低钙十分位定义为校正钙<8.4 mg/dL,参照组为校正钙8.7-8.9 mg/dL。
  • 西那卡塞使用者中HR 1.32(95%CI 1.00, 1.75),全部患者中HR 1.15(95%CI 1.05, 1.26)。

临床怎么用

  • 在透析患者中,尤其西那卡塞使用者,应关注一过性低钙血症与心血管死亡风险的关联。
  • 低钙血症尤其与猝死、出血性卒中、心衰和缺血性心脏病死亡相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calcimimetics are widely used in hemodialysis patients and influence serum calcium levels. Although the Kidney Disease: Improving Global Outcomes guidelines argued that low calcium levels induced by calcimimetics may be harmless, large observational studies investigating the association between hypocalcemia and mortality are scarce. We investigated the association between serum calcium levels and cardiovascular mortality in calcimimetics users using the nationwide Japanese registry for dialysis patients. METHODS: In this 9-year prospective cohort study, the baseline data were collected at the end of 2009. We enrolled patients on maintenance hemodialysis or hemodiafiltration. We employed three models (baseline, time-dependent and time-averaged) to conduct Cox proportional hazard regression analyses. RESULTS: Cinacalcet was prescribed to 12.7% (N = 22 853) at baseline. The median observation period was 98 (interquartile range 40-108) months and 108 (interquartile range 59-108) months in the whole cohort (N = 180 136) and in cinacalcet users, respectively. Three-quarters of survivors at the end of 2019 had continued calcimimetic therapy for 10 years, corresponding to a mean annual dropout rate of 2.9%. Hypocalcemia was not associated with cardiovascular mortality in the baseline or time-averaged model. In the time-dependent model, however, the lowest calcium decile (corrected calcium <8.4 mg/dL) was significantly associated with higher cardiovascular mortality than the reference (corrected calcium 8.7-8.9 mg/dL) in both cinacalcet users and all patients [hazard ratio (95% confidence interval) 1.32 (1.00, 1.75) and 1.15 (1.05, 1.26), respectively]. Hypocalcemia was especially associated with sudden death and death due to hemorrhagic stroke, heart failure and ischemic heart disease. Higher rate of fatal and non-fatal cardiovascular events was observed in hypocalcemic patients regardless of cinacalcet usage. CONCLUSIONS: Our findings suggest that transient hypocalcemia was associated with an increased risk of cardiovascular death independent of cinacalcet usage. We should pay attention to hypocalcemia transiently induced by cinacalcet.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Goto S, Hamano T, Fujii H, et al. Hypocalcemia and cardiovascular mortality in cinacalcet users. Nephrol Dial Transplant. 2024. PMID: 37777840. doi:10.1093/ndt/gfad213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。